Developing improvements in cannabidiol and other cannabinoids from C. sativa, and a computational analysis of the interaction between the cannabinoids and relevant receptors

对来自 C. sativa 的大麻二酚和其他大麻素进行改进，并对大麻素与相关受体之间的相互作用进行计算分析

• 批准号: 530680-2018
• 负责人: Trant, John
• 金额: $ 1.82万
• 依托单位: University of Windsor
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=667036
• 关键词: Developing; improvements; cannabidiol; other; cannabinoids

With the legalization of cannabis in Canada, we expect to see an increase in overt recreational use. However,**THC, the psychoactive cannabinoid is one of only 113 known cannabinoids produced by C. sativa. Preliminary**research has shown that the other cannabinoids, although lacking any psychoactive activity, might have**potentially potent biomedical applications, including for anti-cancer, anti-inflammatory, and local analgesic**activity. They could provide a starting point for developing new classes of therapies from readily available**materials. However, several problems must be addressed before we can advance the field. We need an easily**scalable, simple, and inexpensive method to isolate cannabidiol (CBD) from crude plant extracts in high purity**and yield. We also need an improved understanding of the affinity of CBD and other minor cannabinoids for the**various receptors on cell surfaces as the profile of these interactions determines the physiological effects. This**collaboration between the University of Windsor and Aphria, a leading grower of medical cannabis, seeks to**address both of these issues.

随着加拿大大麻的合法化，我们预计公开的娱乐用途将增加。然而，**THC，精神活性大麻素是由C产生的113种已知大麻素之一。sativa.初步研究表明，其他大麻素虽然缺乏任何精神活性，但可能具有潜在的生物医学应用，包括抗癌，抗炎和局部镇痛活性。它们可以为从现成的材料中开发新的治疗方法提供一个起点。然而，在我们能够推进该领域之前，必须解决几个问题。我们需要一种容易 ** 可扩展的，简单的，廉价的方法来从粗植物提取物中分离大麻二酚（CBD），以获得高纯度 ** 和产量。我们还需要更好地了解CBD和其他次要大麻素对细胞表面各种受体的亲和力，因为这些相互作用的特征决定了生理效应。温莎大学和医用大麻的主要种植者Aphria之间的合作旨在解决这两个问题。